CD274 and neoplasm: The clinical activity of PD-1/PD-L1 antibodies is positively correlated with the integrity of intestinal microbiota and the number of effector T cells in the tumor microenvironment, and modulation of intestinal microbiota composition may be a promising strategy to improve clinical benefit from PD-1/PD-L1 antibodies27,37,42.